Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer.

Patel PH, Chaw CL, Tree AC, Sharabiani M, van As NJ.

World J Urol. 2019 Jul 25. doi: 10.1007/s00345-019-02873-w. [Epub ahead of print]

PMID:
31346760
2.

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.

Kneebone A, Hruby G, Ainsworth H, Byrne K, Brown C, Guo L, Guminski A, Eade T.

Eur Urol Oncol. 2018 Dec;1(6):531-537. doi: 10.1016/j.euo.2018.04.017. Epub 2018 May 23.

PMID:
31158100
3.

Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases.

Yeung R, Hamm J, Liu M, Schellenberg D.

Radiat Oncol. 2017 Jun 21;12(1):105. doi: 10.1186/s13014-017-0820-1.

4.

Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.

Muldermans JL, Romak LB, Kwon ED, Park SS, Olivier KR.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):696-702. doi: 10.1016/j.ijrobp.2016.01.032. Epub 2016 Jan 29.

5.

Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.

Ouyang W, Yu J, Nuerjiang S, Li Z, Wang D, Wang X, Zhang J, Xie C.

Cancer Med. 2019 Jun 27. doi: 10.1002/cam4.2366. [Epub ahead of print]

6.

Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).

Habl G, Straube C, Schiller K, Duma MN, Oechsner M, Kessel KA, Eiber M, Schwaiger M, K├╝bler H, Gschwend JE, Combs SE.

BMC Cancer. 2017 May 22;17(1):361. doi: 10.1186/s12885-017-3341-2.

7.

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.

Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T, De Vos F, Huysse W, Hautekiet A, Maes G, Ost P.

Radiat Oncol. 2014 Jun 12;9:135. doi: 10.1186/1748-717X-9-135.

8.

Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.

Bouman-Wammes EW, van Dodewaard-De Jong JM, Dahele M, Cysouw MCF, Hoekstra OS, van Moorselaar RJA, Piet MAH, Verberne HJ, Bins AD, Verheul HMW, Slotman BJ, Oprea-Lager DE, Van den Eertwegh AJM.

Clin Genitourin Cancer. 2017 Oct;15(5):e773-e782. doi: 10.1016/j.clgc.2017.03.009. Epub 2017 Mar 29.

PMID:
28462855
9.

Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases.

Fanetti G, Marvaso G, Ciardo D, Rese A, Ricotti R, Rondi E, Comi S, Cattani F, Zerini D, Fodor C, de Cobelli O, Orecchia R, Jereczek-Fossa BA.

Med Oncol. 2018 Apr 18;35(5):75. doi: 10.1007/s12032-018-1137-0.

PMID:
29671075
10.

Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.

Agolli L, Bracci S, Nicosia L, Valeriani M, De Sanctis V, Osti MF.

Clin Colorectal Cancer. 2017 Mar;16(1):58-64. doi: 10.1016/j.clcc.2016.07.004. Epub 2016 Jul 18.

PMID:
27522627
11.

Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.

Ost P, Jereczek-Fossa BA, Van As N, Zilli T, Tree A, Henderson D, Orecchia R, Casamassima F, Surgo A, Miralbell R, De Meerleer G.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e115-20. doi: 10.1016/j.clon.2016.04.040. Epub 2016 Apr 28.

PMID:
27133946
12.

The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer.

Franzese C, Zucali PA, Di Brina L, D'Agostino G, Navarria P, Franceschini D, Santoro A, Scorsetti M.

Cancer Med. 2018 Sep;7(9):4379-4386. doi: 10.1002/cam4.1707. Epub 2018 Aug 2.

13.

Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.

Collen C, Christian N, Schallier D, Meysman M, Duchateau M, Storme G, De Ridder M.

Ann Oncol. 2014 Oct;25(10):1954-9. doi: 10.1093/annonc/mdu370. Epub 2014 Aug 11.

PMID:
25114022
14.

Salvage Stereotactic Body Radiotherapy for Patients With Prostate Cancer With Isolated Lymph Node Metastasis: A Single-Center Experience.

Ponti E, Ingrosso G, Carosi A, Di Murro L, Lancia A, Pietrasanta F, Santoni R.

Clin Genitourin Cancer. 2015 Aug;13(4):e279-e284. doi: 10.1016/j.clgc.2014.12.014. Epub 2014 Dec 30.

PMID:
25604915
15.

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer.

Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR.

Front Oncol. 2013 Jan 22;2:215. doi: 10.3389/fonc.2012.00215. eCollection 2012.

16.

SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer.

Azzam G, Lanciano R, Arrigo S, Lamond J, Ding W, Yang J, Hanlon A, Good M, Brady L.

Front Oncol. 2015 May 5;5:101. doi: 10.3389/fonc.2015.00101. eCollection 2015.

17.

Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience.

Ingrosso G, Trippa F, Maranzano E, Carosi A, Ponti E, Arcidiacono F, Draghini L, Di Murro L, Lancia A, Santoni R.

World J Urol. 2017 Jan;35(1):45-49. doi: 10.1007/s00345-016-1860-0. Epub 2016 May 27.

PMID:
27233779
18.

Prognostic Value of [18F]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.

Cysouw M, Bouman-Wammes E, Hoekstra O, van den Eertwegh A, Piet M, van Moorselaar J, Boellaard R, Dahele M, Oprea-Lager D.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):406-410. doi: 10.1016/j.ijrobp.2018.02.005. Epub 2018 Feb 13.

PMID:
29559285
19.

Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective?

Jereczek-Fossa BA, Ronchi S, Orecchia R.

Rep Pract Oncol Radiother. 2015 Nov-Dec;20(6):472-83. doi: 10.1016/j.rpor.2014.10.004. Epub 2014 Nov 7.

20.

Supplemental Content

Support Center